Table 2. Measures of Apathy at 6 Months in Persons With Alzheimer Disease Participating in the ADMET 2 Trial.
| Characteristic | No. (%) | |
|---|---|---|
| Methylphenidate group | Placebo group | |
| No. of participants with data at 6 mo | 89 | 91 |
| NPI apathy subscale | ||
| Score at 6 mo, mean (SD) | 3.5 (3.4) | 4.6 (3.3) |
| Change from baseline to 6 mo, mean (SD) | −4.5 (4.1) | −3.1 (3.6) |
| Estimated treatment effect (methylphenidate – placebo), mean (95% CI)a,b | −1.25 (−2.03 to −0.47) | |
| P value | .002 | |
| Cohen d | 0.365 | |
| ADCS-CGIC change in apathy at 6 mo | ||
| Improvement | ||
| Marked | 2 (2.2) | 2 (2.2) |
| Moderate | 14 (15.7) | 10 (11.0) |
| Minimal | 23 (25.8) | 20 (22.0) |
| No change | 42 (47.2) | 40 (44.0) |
| Worsening | ||
| Minimal | 7 (7.9) | 16 (17.6) |
| Moderate | 1 (1.1) | 3 (3.3.) |
| Marked | 0 (.00) | 0 (0.0) |
| Estimated treatment effect (methylphenidate vs placebo), OR (95% CI)b | 1.90 (0.95-3.84) | |
| P value | .07 | |
| Estimated difference in mean change from baseline to 6 mo (methylphenidate vs placebo), OR (95% CI)c | 1.43 (1.00-2.04) | |
| P value | .048 | |
Abbreviations: ADCS-CGIC, Alzheimer’s Disease Cooperative Study Clinical Global Impression of Change; ADMET, Apathy in Dementia Methylphenidate Trial; NPI, Neuropsychiatric Inventory; OR, odds ratio.
a
Estimated in a longitudinal model for mean difference between arms in change from baseline, using a linear mixed model with random intercept for each participant, adjusting for clinic, age, sex, and diabetes condition.
b
Estimated difference in proportional odds of improvement at 6 months.
c
Estimated in a longitudinal model for mean difference between arms in change from baseline, for all follow-up visits, adjusted for clinic, participant sex, and diabetes condition.